Biomarkers, the control panel and personalized <scp>C

Respirology
21, 24-33
DOI: 10.1111/resp.12585

Citation Report

#	Article	IF	Citations
1	Lung perfusion and emphysema distribution affect the outcome of endobronchial valve therapy. International Journal of COPD, 2016, 11, 1245.	2.3	20
2	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 541-549.	5.6	73
4	Adding biological markers to COPD categorisation schemes: a way towards more personalised care?. European Respiratory Journal, 2016, 47, 1601-1605.	6.7	6
5	Phenotypes contribute to treatments. European Respiratory Journal, 2017, 49, 1700054.	6.7	0
6	Year in review 2016: <scp>Chronic obstructive pulmonary disease</scp> and asthma. Respirology, 2017, 22, 820-828.	2.3	3
7	COPD: Lessons learned, forging a fantastic future. Respirology, 2017, 22, 632-633.	2.3	3
8	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987.	13.7	78
9	Phenotypes in obstructive sleep apnea: A definition, examples and evolution of approaches. Sleep Medicine Reviews, 2017, 35, 113-123.	8.5	208
10	COPD: algorithms and clinical management. European Respiratory Journal, 2017, 50, 1701733.	6.7	3
11	The value of blood cytokines and chemokines in assessing COPD. Respiratory Research, 2017, 18, 180.	3.6	83
12	Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease. Journal of Thoracic Disease, 2017, 9, 1509-1516.	1.4	41
13	Stable-State Midrange Proadrenomedullin IsÂAssociated With Severe Exacerbations inÂCOPD. Chest, 2018, 154, 51-57.	0.8	12
14	Stable COPD Treatment: Where are We?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 123-129.	1.6	8
15	Recognizable clinical subtypes of obstructive sleep apnea across international sleep centers: a cluster analysis. Sleep, 2018, 41, .	1.1	148
16	Treatable traits of chronic airways disease. Current Opinion in Pulmonary Medicine, 2018, 24, 24-31.	2.6	24
17	Comparing severity scores in exacerbations of chronic obstructive pulmonary disease. Clinical Respiratory Journal, 2018, 12, 2668-2675.	1.6	8
18	Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD). Expert Review of Proteomics, 2018, 15, 923-935.	3.0	21
19	COPD stands for complex obstructive pulmonary disease. European Respiratory Review, 2018, 27, 180027.	7.1	32

#	Article	IF	Citations
20	Las bronquiectasias: una enfermedad compleja y heterogÃ©nea. Archivos De Bronconeumologia, 2019, 55, 427-433.	0.8	16
21	Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respiratory Research, 2019, 20, 152.	3.6	34
22	Bronchiectasis: A Complex, Heterogeneous Disease. Archivos De Bronconeumologia, 2019, 55, 427-433.	0.8	7
23	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy, 2019, 23, 603-614.	3.8	15
24	The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD. Annals of Medicine, 2019, 51, 314-329.	3.8	24
25	The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2019, 55, 93-99.	0.8	5
26	Electrochemical methods for detection of biomarkers of Chronic Obstructive Pulmonary Disease in serum and saliva. Biosensors and Bioelectronics, 2019, 142, 111453.	10.1	35
27	Novel therapeutic targets and drug development for the precision treatment of COPD. Expert Review of Precision Medicine and Drug Development, 2019, 4, 121-128.	0.7	3
28	Precision medicine in obstructive sleep apnoea. Lancet Respiratory Medicine,the, 2019, 7, 456-464.	10.7	91
29	Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. European Respiratory Journal, 2019, 53, 1802058.	6.7	177
30	Proyecto de biomarcadores y perfiles clÃnicos personalizados en la enfermedad pulmonar obstructiva crÃ³nica (proyecto BIOMEPOC). Archivos De Bronconeumologia, 2019, 55, 93-99.	0.8	18
31	COPD 2020: changes and challenges. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L879-L883.	2.9	66
32	Correlation of Arterial CO2 and Respiratory Impedance Values among Subjects with COPD. Journal of Clinical Medicine, 2020, 9, 2819.	2.4	1
33	Salivary Metabolic Profile of Patients with Lung Cancer, Chronic Obstructive Pulmonary Disease of Varying Severity and Their Comorbidity: A Preliminary Study. Diagnostics, 2020, 10, 1095.	2.6	2
34	Measuring disease activity in COPD: is clinically important deterioration the answer?. Respiratory Research, 2020, 21, 134.	3.6	18
35	A perspective for chronic obstructive pulmonary disease (COPD) management: six key clinical questions to improve disease treatment. Expert Opinion on Pharmacotherapy, 2021, 22, 427-437.	1.8	5
36	Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease. Internal and Emergency Medicine, 2021, 16, 559-569.	2.0	9
37	Probing Cellular and Molecular Mechanisms of Cigarette Smoke-Induced Immune Response in the Progression of Chronic Obstructive Pulmonary Disease Using Multiscale Network Modeling. PLoS ONE, 2016, 11, e0163192.	2.5	14

#	Article	IF	Citations
38	When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment. International Journal of COPD, 2020, Volume 15, 3375-3384.	2.3	4
39	The processes of inflammation and fibrosis in patients with chronic obstructive pulmonary disease. Medicni Perspektivi, 2020, 25, 59-65.	0.4	0
40	Novel Applications of Biomarkers in Chronic Obstructive Pulmonary Disease. , 2022, , 425-439.		0
41	An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. American Journal of Respiratory and Critical Care Medicine, 2023, 208, 374-394.	5.6	3
42	The genomic landscape of chronic obstructive pulmonary disease: Insights from nutrigenomics. Clinical Nutrition ESPEN, 2024, 59, 29-36.	1.2	0